547 related articles for article (PubMed ID: 33153817)
41. A global phase II randomized trial comparing oral taxane ModraDoc006/r to intravenous docetaxel in metastatic castration resistant prostate cancer.
Vaishampayan UN; Keessen M; Dreicer R; Heath EI; Buchler T; Árkosy PF; Csöszi T; Wiechno P; Kopyltsov E; Orlov SV; Plekhanov A; Smagina M; Varlamov S; Shore ND
Eur J Cancer; 2024 May; 202():114007. PubMed ID: 38518534
[TBL] [Abstract][Full Text] [Related]
42. Impact of DNA damage repair defects and aggressive variant features on response to carboplatin-based chemotherapy in metastatic castration-resistant prostate cancer.
Slootbeek PHJ; Duizer ML; van der Doelen MJ; Kloots ISH; Kuppen MCP; Westgeest HM; Uyl-de Groot CA; Pamidimarri Naga S; Ligtenberg MJL; van Oort IM; Gerritsen WR; Schalken JA; Kroeze LI; Bloemendal HJ; Mehra N
Int J Cancer; 2021 Jan; 148(2):385-395. PubMed ID: 32965028
[TBL] [Abstract][Full Text] [Related]
43. ZD1839 (IRESSA), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells.
Ciardiello F; Caputo R; Borriello G; Del Bufalo D; Biroccio A; Zupi G; Bianco AR; Tortora G
Int J Cancer; 2002 Mar; 98(3):463-9. PubMed ID: 11920601
[TBL] [Abstract][Full Text] [Related]
44. Understanding taxanes in prostate cancer; importance of intratumoral drug accumulation.
de Morrée E; van Soest R; Aghai A; de Ridder C; de Bruijn P; Ghobadi Moghaddam-Helmantel I; Burger H; Mathijssen R; Wiemer E; de Wit R; van Weerden W
Prostate; 2016 Jul; 76(10):927-36. PubMed ID: 26997363
[TBL] [Abstract][Full Text] [Related]
45. Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA.
Sumanasuriya S; Seed G; Parr H; Christova R; Pope L; Bertan C; Bianchini D; Rescigno P; Figueiredo I; Goodall J; Fowler G; Flohr P; Mehra N; Neeb A; Rekowski J; Eisenberger M; Sartor O; Oudard S; Geffriaud-Ricouard C; Ozatilgan A; Chadjaa M; Macé S; Lord C; Baxter J; Pettitt S; Lambros M; Sharp A; Mateo J; Carreira S; Yuan W; de Bono JS
Eur Urol; 2021 Aug; 80(2):243-253. PubMed ID: 34103179
[TBL] [Abstract][Full Text] [Related]
46. Platinum compounds in the treatment of advanced breast cancer.
Martín M
Clin Breast Cancer; 2001 Oct; 2(3):190-208; discussion 209. PubMed ID: 11899413
[TBL] [Abstract][Full Text] [Related]
47. TMPRSS2-ERG in Blood and Docetaxel Resistance in Metastatic Castration-resistant Prostate Cancer.
Reig Ò; Marín-Aguilera M; Carrera G; Jiménez N; Paré L; García-Recio S; Gaba L; Pereira MV; Fernández P; Prat A; Mellado B
Eur Urol; 2016 Nov; 70(5):709-713. PubMed ID: 26948395
[TBL] [Abstract][Full Text] [Related]
48. DNA-PKc inhibition overcomes taxane resistance by promoting taxane-induced DNA damage in prostate cancer cells.
Chao OS; Goodman OB
Prostate; 2021 Oct; 81(14):1032-1048. PubMed ID: 34297853
[TBL] [Abstract][Full Text] [Related]
49. Overcoming EZH2 Inhibitor Resistance by Taxane in PTEN-Mutated Cancer.
Ma L; Yan Y; Bai Y; Yang Y; Pan Y; Gang X; Karnes RJ; Zhang J; Lv Q; Wu Q; Huang H
Theranostics; 2019; 9(17):5020-5034. PubMed ID: 31410199
[No Abstract] [Full Text] [Related]
50. Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSF.
Aggarwal RR; Beer TM; Weinberg VK; Higano C; Taplin ME; Ryan CJ; Lin AM; Alumkal J; Graff JN; Nordquist LT; Herrera I; Small EJ
Clin Genitourin Cancer; 2015 Jun; 13(3):e191-8. PubMed ID: 25557266
[TBL] [Abstract][Full Text] [Related]
51. Loss of SLCO1B3 drives taxane resistance in prostate cancer.
de Morrée ES; Böttcher R; van Soest RJ; Aghai A; de Ridder CM; Gibson AA; Mathijssen RH; Burger H; Wiemer EA; Sparreboom A; de Wit R; van Weerden WM
Br J Cancer; 2016 Sep; 115(6):674-81. PubMed ID: 27537383
[TBL] [Abstract][Full Text] [Related]
52. Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients.
Azad AA; Eigl BJ; Murray RN; Kollmannsberger C; Chi KN
Eur Urol; 2015 Jan; 67(1):23-29. PubMed ID: 25018038
[TBL] [Abstract][Full Text] [Related]
53. The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer.
Pomerantz MM; Spisák S; Jia L; Cronin AM; Csabai I; Ledet E; Sartor AO; Rainville I; O'Connor EP; Herbert ZT; Szállási Z; Oh WK; Kantoff PW; Garber JE; Schrag D; Kibel AS; Freedman ML
Cancer; 2017 Sep; 123(18):3532-3539. PubMed ID: 28608931
[TBL] [Abstract][Full Text] [Related]
54. Treatment of Metastatic Castration-resistant Prostate Cancer: Are PARP Inhibitors Shifting the Paradigm?
Fujimoto N; Harada K; Shiota M; Tomisaki I; Minato A; Nagata Y; Kimuro R; Harada M; Fujisawa M
Anticancer Res; 2021 Oct; 41(10):4687-4695. PubMed ID: 34593416
[TBL] [Abstract][Full Text] [Related]
55. Germline BRCA mutation does not prevent response to taxane-based therapy for the treatment of castration-resistant prostate cancer.
Gallagher DJ; Cronin AM; Milowsky MI; Morris MJ; Bhatia J; Scardino PT; Eastham JA; Offit K; Robson ME
BJU Int; 2012 Mar; 109(5):713-9. PubMed ID: 21756279
[TBL] [Abstract][Full Text] [Related]
56. Taxane-platinum combinations in advanced non-small cell lung cancer: a review.
Rigas JR
Oncologist; 2004; 9 Suppl 2():16-23. PubMed ID: 15161987
[TBL] [Abstract][Full Text] [Related]
57. Effect of Taxane Plus Platinum Regimens vs Doxorubicin Plus Cisplatin as Adjuvant Chemotherapy for Endometrial Cancer at a High Risk of Progression: A Randomized Clinical Trial.
Nomura H; Aoki D; Michimae H; Mizuno M; Nakai H; Arai M; Sasagawa M; Ushijima K; Sugiyama T; Saito M; Tokunaga H; Matoda M; Nakanishi T; Watanabe Y; Takahashi F; Saito T; Yaegashi N;
JAMA Oncol; 2019 Jun; 5(6):833-840. PubMed ID: 30896757
[TBL] [Abstract][Full Text] [Related]
58. Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.
Yasumizu Y; Miyajima A; Kosaka T; Miyazaki Y; Kikuchi E; Oya M
J Urol; 2014 Jan; 191(1):227-34. PubMed ID: 23954373
[TBL] [Abstract][Full Text] [Related]
59. Serum testosterone level as possible predictive marker in androgen receptor axis-targeting agents and taxane chemotherapies for castration-resistant prostate cancer.
Shiota M; Kashiwagi E; Murakami T; Takeuchi A; Imada K; Inokuchi J; Tatsugami K; Eto M
Urol Oncol; 2019 Mar; 37(3):180.e19-180.e24. PubMed ID: 30446464
[TBL] [Abstract][Full Text] [Related]
60. Complete response with early introduction of cabazitaxel in a patient with multiple lung metastases of castration-resistant prostate cancer following the early detection of metastases using liquid biopsy: a case report.
Kosaka T; Hongo H; Oya M
BMC Cancer; 2019 Jun; 19(1):562. PubMed ID: 31185946
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
